title: Assessment of genetic risk factors for thromboembolic complications in adults with idiopathic nephrotic syndrome.
abstract: OBJECTIVE
  Nephrotic syndrome (NS) may occur with acquired hypercoagulability, however, the fact that it is accompanied by an underlying hereditary thrombophilia, especially combined hereditary thrombophilia would lead to thrombotic events. In this study, we aimed to evaluate the contribution of genetic thrombophilia to development of thrombotic events in adult patients with NS.
  
  
  METHODS
  Factor V Leiden (FVL), prothrombin, and methylenetetrahydrofolate reductase (MTHFR) gene mutation were studied in 51 newly diagnosed idiopathic NS patients and age- and gender-matched 20 healthy control subjects included in the study. Renal vein Doppler ultrasound was conducted in order to investigate the prevalence of subclinical renal vein thrombosis.
  
  
  RESULTS
  Of 51 patients, 6 (11.8%) were established to have thromboembolic (TE) complications at the time of diagnosis (4 symptomatic, 2 subclinical), and no recurring thrombotic episode was observed. Genetic mutation was established in all patients that were found to have TE complications. Acquired hypercoagulability factors were similar in patients without and with TE complication.
  
  
  CONCLUSIONS
  The coexistence of inherited thrombophilia in NS may facilitate thromboembolic complications. If the cause of thrombosis cannot be explained by the usual factors attributed to the occurrence of thrombosis in NS, screening for the other factors, such as FVL, MTHFR, and prothrombin gene mutation, may be beneficial.
authors: Division of Nephrology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
authors: Melisa
authors: M
authors: Sahin
authors: Sultan
authors: S
authors: Ozkurt
authors: Nevbahar Akcar
authors: NA
authors: Degirmenci
authors: Ahmet
authors: A
authors: Musmul
authors: Gokhan
authors: G
authors: Temiz
authors: Mehmet
authors: M
authors: Soydan
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005165:Factor V / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D009404:Nephrotic Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D011379:Prognosis; D011446:Prospective Studies; D011516:Prothrombin / Q000235:genetics; D012082:Renal Veins / Q000000981:diagnostic imaging; D018570:Risk Assessment; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D016896:Treatment Outcome; D014463:Ultrasonography; D054556:Venous Thromboembolism / Q000175:diagnosis / Q000209:etiology / Q000235:genetics*
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2)